Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Bullboard - Stock Discussion Forum Iterum Therapeutics plc ITRM

Iterum Therapeutics plc is a clinical-stage pharmaceutical company. The Company develops differentiated anti-infectives aimed at combatting the global crisis of multi-drug resistant pathogens to significantly improve the lives of people affected by serious and life-threatening diseases around the world. It is advancing its first compound, sulopenem, a novel penem anti-infective compound, in... see more

NDAQ:ITRM - Post Discussion

Iterum Therapeutics plc > Iterum Therapeutics to Host Morning Conference Call on U.S.
View:
Post by whytestocks on Oct 28, 2024 5:32am

Iterum Therapeutics to Host Morning Conference Call on U.S.

Just In: $ITRM Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH(TM) (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract InfectionsIterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH™ (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections PR Newswire Monday, October 28, 2024 , at 8:30 a.m. EDT DUBLIN and CHICAGO , ...ITRM - Iterum Therapeutics to Host Morning Conference Call on U.S. FDA Approval of ORLYNVAH(TM) (Oral Sulopenem) for the Treatment of Uncomplicated Urinary Tract Infections
Comment by Ltcguy2001 on Oct 28, 2024 8:02pm
I was lucky to take a small 5,000 share position last Thursday @$1.20 and sold Friday at $2.18.  Took my $6k back off the table but bought 3,500 @$1.40 with left over.  Free and clear long hold.  Might do it again if the market lets me.
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.

{{currentVideo.companyName}}
{{currentVideo.intervieweeName}}{{currentVideo.intervieweeTitle}}
< Previous
Next >
Dealroom for high-potential pre-IPO opportunities